Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer

Journal of Clinical Oncology

Volumn 25, Issue 10, 2007, Pages 1232-1238

  Limentani, Steven A ^a   Brufsky, Adam M ^a   Erban, John K ^a   Jahanzeb, Mohammed ^a   Lewis, Deborah ^a  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; QUINOLONE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; TAXOID; VINBLASTINE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; EPIPHORA; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HEADACHE; HUMAN; LOADING DRUG DOSE; LUNG TOXICITY; LYMPH NODE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONYCHOLYSIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SINUS TACHYCARDIA; SINUSITIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT DISEASE; BREAST TUMOR; CHEMISTRY; FEMALE; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TAXOIDS; VINBLASTINE;

EID: 34247100686     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.3306     Document Type: Article

References (50)

1. National Comprehensive Cancer Network (NCCN): Breast Cancer. Clinical Practice Guidelines in Oncology, v. 1.2007. http://nccn.org/professionals/ physician_gls/default.asp
2. Costa SD, von Minckwitz G, Raab G, et al: The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 26:24-31, 1999 (suppl 9)
3. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
4. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
5. Trudeau ME: Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer. Semin Oncol 26:21-26, 1999 (suppl 8)
6. Burris HA III: Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 26:1-6, 1999 (suppl 9)
7. Ganem G, Tubiana-Hulin M, Fumoleau P, et al: Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:1623-1628, 2003
8. Gradishar WJ, Loh K, Erban J, et al: Preliminary results from a phase II study of (Taxotere® [T]) docetaxel as primary chemotherapy (PCT) followed by doxorubicin (A) and cyclophosphamide (C) in stage III breast cancer. Breast Cancer Res Treat 46:74, 1997 (abstr 310)
9. Paciucci PA, Raptis G, Bleiweiss I, et al: Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs 13:791-795, 2002
10. von Minckwitz G, Costa SD, Eiermann W, et al: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999-2005, 1999
11. Domenech GH, Vogel CL: A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2:113-128, 2001
12. Johnson SA, Harper P, Hortobagyi GN, et al: Vinorelbine: An overview. Cancer Treat Rev 22:127-142, 1996
13. Dieras V, Fumoleau P, Kalla S, et al: Docetaxel in combination with doxorubicin or vinorelbine. Eur J Cancer 33:S20-S22, 1997 (suppl 7)
14. Lavelle F, Bissery MC, Combeau C, et al: Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22:3-16, 1995 (suppl 4)
15. De Paz L, Lluch A, Martin M, et al: A phase II study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18:119a, 1999 (abstr 452)
16. Gómez-Bernal A, Cruz JJ, García Palomo A, et al: Docetaxel and vinorelbine in patients with metastatic breast cancer after using anthracyclines. Breast Cancer Res Treat 57:87, 1999 (abstr 341)
17. Gómez-Bernal A, Cruz JJ, García-Palomo A, et al: Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: A multicenter phase II study. Am J Clin Oncol 26:127-131, 2003
18. Gralow JR, Ellis GK, Williams MA, et al: Docetaxel + vinorelbine with concurrent G-CSF support: A phase II study in stage IV breast cancer. Breast Cancer Res Treat 57:88, 1999 (abstr 347)
19. Miller VA, Krug LM, Ng KK, et al: Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:1346-1350, 2000
20. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
21. Press MF, Pike MC, Chazin VR, et al: Her-2/ neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
22. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
23. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
24. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
25. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
26. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
27. Kuzur ME, Albain KS, Huntington MO, et al: A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Am Soc Clin Oncol 19:131a, 2000 (abstr 512)
28. Tedesco KL, Thor AD, Johnson DH, et al: Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial. J Clin Oncol 22:1071-1077, 2004
29. Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895, 2003
30. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
31. + metastatic breast cancer. Oncologist 7:410-417, 2002
32. Pegram MD, Lopez A, Konecny G, et al: Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 27:21-25, 2000 (suppl 11)
33. Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004
34. Limentani SA, Brufsky AM, Erban JK, et al: Phase II study of neoadjuvant docetaxel/vinorelbine followed by surgery and adjuvant doxorubicin/ cyclophosphamide in women with stage II/III breast cancer. Clin Breast Cancer 6:511-517, 2006
35. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
36. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5, 2005 (suppl 1; abstr 1)
37. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
38. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
39. Bear HD, Anderson S, Smith RE, et al: A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients with operable carcinoma of the breast: Results of NSABP B-27. Breast Cancer Res Treat 88:S16, 2004 (suppl 1; abstr 26)
40. von Minckwitz G, Raab G, Caputo A, et al: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685, 2005
41. von Minckwitz G, Blohmer J-U, Raab G, et al: In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 16:56-63, 2005
42. Gori S, Colozza M, Mosconi AM, et al: Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 90:36-40, 2004
43. Fountzilas G, Christodoulou C, Tsavdaridis D, et al: Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 22:655-662, 2004
44. Janku F, Pribylova O, Zimovjanova M, et al: 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: Single institution prospective study. Bull Cancer 91: E279-E283, 2004
45. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 23:4265-4274, 2005
46. Montemurro F, Choa G, Faggiuolo R, et al: A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 66:38-45, 2004
47. Pegram MD, Pienkowski T, Northfelt DW, et al: Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96:759-769, 2004
48. Raff JP, Rajdev L, Malik U, et al: Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 4:420-427, 2004
49. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
50. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005